|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The glucagon-like peptide-1 (GLP-1) agonists, liraglutide and semaglutide, have been shown to reduce major CV events, but did not affect rates of hospitalization for HF.
|
29270818 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Consequently, GLP-1 RA drugs in addition to conventional hypoglycemic therapy may reduce hospital admissions for heart failure worsening, by increasing CRTd responders rate.Trial registration NCT03282136.
|
30348145 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, no statistically significant reduction was observed with GLP-1 agonists in terms of reducing non-fatal MI (RR 0.95, 95% CI: 0.86-1.04), non-fatal stroke events (RR 0.89, 95% CI: 0.76-1.03), and rates of HF hospitalisation (RR 0.94, 95% CI: 0.84-1.04).
|
29887418 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The role of neprilysin in the metabolism of endogenous GLP-1 and long-acting GLP-1 analogues points to a range of potential pathophysiological effects that may be clinically relevant to patients with heart failure, with or without diabetes.
|
29603541 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Low fasting plasma glucose and increased glucagon are robust metabolic predictors of adverse events in advanced HF.
|
28784650 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The GLP-1 agonist liraglutide was recently shown to reduce cardiovascular and all-cause mortality, yet hospitalization for HF was not significantly reduced.
|
27653447 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Findings from recently completed trials indicate that a GLP-1 RA-induced increase in HR, regardless of magnitude, does not present an increased cardiovascular risk for subjects with T2DM, although a pronounced increase in HR may be associated with adverse clinical outcomes in those with advanced heart failure.
|
28086882 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
A1C = hemoglobin A1C ACS = acute coronary syndrome CHD = coronary heart disease CI = confidence interval CV = cardiovascular CVOT = Cardiovascular Outcome Trial DPP-4 = dipeptidyl peptidase 4 FDA = U.S. Food and Drug Administration GIP = glucose-dependent insulinotropic polypeptide GLP-1 = glucagon-like protein 1 GLP-1 RA = glucagon-like protein 1 receptor agonist HF = heart failure HR = hazard ratio LVEF = left ventricular ejection fraction MACE = major adverse cardiovascular events MI = myocardial infarction T2D = type 2 diabetes.
|
27819769 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide 1 agonists have shown trends towards improvement of heart failure parameters.
|
27195949 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Disturbances in calcium cycling are characteristic of heart failure (HF); therefore, the aim of this study was to investigate the effect of exendin-4 (a GLP-1 mimetic) on the regulation of calcium handling and to identify the underlying mechanisms in an HF rat model after myocardial infarction (MI).
|
28242257 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
After matching each GLP-1 analog user to a sulfonylurea user on the time-conditional propensity scores from prescription-based exposure sets, the hazard ratio of heart failure with GLP-1 use was 0.73 (95%CI: 0.57-0.93).
|
27610604 |
2017 |
|
Heart failure
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Use of glucagon to treat neonatal low-output congestive heart failure after maternal labetalol therapy.
|
7608802 |
1995 |